Vital signs

Blue Spark Technologies Adds MaryAnne Rizk to Board of Advisors

Retrieved on: 
Thursday, January 4, 2024
RWD, CVS, Drug development, FDA, Health, DHT, Record, Heart, RPM, Temperature, Knowledge, DCT, Merck, Organization, Vital signs, Personalized medicine, Medical device

CLEVELAND, Jan. 4, 2024 /PRNewswire/ -- Blue Spark Technologies, Inc., a proven innovative digital health technology (DHT) leader in enabling AI-powered remote patient monitoring (RPM) to support precision patient-centric drug development, proudly announces the appointment of Dr. MaryAnne Rizk, a recognized leader in drug development technological innovation, to the Company's advisory board.

Key Points: 
  • Dr. Rizk will work with Blue Spark Technologies to identify the evolution of its integrated growth.
  • "We are incredibly fortunate to welcome Dr. Rizk to our advisory board," said John Gannon, President and CEO of Blue Spark Technologies.
  • I am confident that the collective expertise of our board will further propel Blue Spark Technologies to new heights of success."
  • "I am thrilled to be appointed to the Board of Advisors for Blue Spark Technologies," stated Dr. Rizk.

Sharp Unveils Cutting-Edge Technologies at CES 2024

Retrieved on: 
Tuesday, January 2, 2024
Carbon, Sharp Corporation, LCD, Central Hall, IGZO, Distracted driving, Ion mobility spectrometry, Suction, Glasses, Sustainability, Better Life, Household, Gold, 0W, Cooking, CE, XR, AI, AQUOS, Future, Exhibition, Sharp, Noise, Electronics, Las Vegas Convention Center, Orientation, CES, Safety, Vital signs, Communication, Vacuum, Somnolence

MONTVALE, N.J., Jan. 2, 2024 /PRNewswire/ -- Sharp, a global leader in innovative technology solutions, is bringing the future to the five senses at CES 2024, taking place in Las Vegas, Nevada, from January 9 to 12, 2024.   Experience products and components that will extend your sight, please your taste buds, detect the slightest differences in scents, replace traditionally loud household products with quiet alternatives, and even feel your heartbeat with miniature wearable devices to read your vital signs.

Key Points: 
  • MONTVALE, N.J., Jan. 2, 2024 /PRNewswire/ -- Sharp, a global leader in innovative technology solutions, is bringing the future to the five senses at CES 2024, taking place in Las Vegas, Nevada, from January 9 to 12, 2024.
  • "As Sharp celebrates its 111th anniversary, Sharp is proud to lead the way in innovation and game-changing technologies," said Jeff Ashida, Chairman, President & CEO of Sharp Electronics Corporation.
  • Sharp will present technologies designed to boost speed and efficiency across various sectors in the Smart Industry section.
  • Sharp  invites attendees, media, and industry professionals to experience the future of technology at CES 2024.

Medical Technology Innovator Thornhill Medical’s MOVES® SLC™ is acquired for United States Marine Corp En Route Care Modernization and added to Authorized Medical Allowance List (AMAL) 647

Retrieved on: 
Wednesday, December 6, 2023
Trauma, Suction, Marine Corps Expeditionary Medal, Medicine, Acquisition, United States Navy, Role, Oxygen, AMAL, Transport, Patient, USMC, Nursing care plan, Vital signs, VADM, Military medicine, Hospital

TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Medical technology innovator Thornhill Medical is pleased to announce that the United States Marine Corps (USMC) has acquired its integrated life support technology, MOVES® SLC™.

Key Points: 
  • TORONTO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Medical technology innovator Thornhill Medical is pleased to announce that the United States Marine Corps (USMC) has acquired its integrated life support technology, MOVES® SLC™.
  • The acquisition supports USMC En Route Care modernization goals using state-of-the-art, lightweight, critical care equipment to successfully transport patients from Role 2 to Role 3 care.
  • MOVES® SLC™ has also been formally added to the U.S. Marine Corps’ Authorized Medical Allowance List (AMAL) 647 for En Route Care.
  • The game-changing MOVES® SLC™ system addresses the need for medical technology that is smaller, lighter, more durable, flexible and easy to maintain, and less reliant on supply chain.

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Retrieved on: 
Tuesday, December 5, 2023
BAL, Movement, Natural killer T cell, Bronchoalveolar lavage, IPF, Blood, Doctor of Philosophy, Pharmacokinetics, Serum, Oxygen, Biomarker, Interim, GRI, Safety, Vital signs, NKT

LA JOLLA, CA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. Patient dosing is expected imminently. Interim data from the Phase 2a biomarker study is expected in the first half of 2024 and topline results are expected in the second half of 2024.

Key Points: 
  • Interim data from the Phase 2a biomarker study is expected in the first half of 2024 and topline results are expected in the second half of 2024.
  • IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream.
  • “The start of enrollment marks another important step forward for GRI as we continue to execute our clinical development plans for our lead program, GRI-0621.
  • We are pleased to meet this significant milestone and remain focused on the successful execution of this Phase 2a study.

IRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by Forbes

Retrieved on: 
Thursday, November 30, 2023
Real estate investment trust, MRI, FactSet, Capital, Growth, Vital signs

WINTER SPRING, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named on Forbes’ latest list of America’s Most Successful Small-Cap Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

Key Points: 
  • WINTER SPRING, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named on Forbes’ latest list of America’s Most Successful Small-Cap Companies for 2024.
  • To help investors find 100 “diamonds in the rough,” Forbes used data from FactSet to compile its annual list of America’s Most Successful Small-Cap Companies.
  • Financial institutions, REITs, utilities, royalty trusts, and limited partnerships were excluded, as were companies that had been public for less than one year.
  • “Climbing the ranks of Forbes’ prestigious list of the top 100 of America’s Most Successful Small-Cap Companies for 2024 is an inspiring milestone for us,” said Roger Susi, President and Chief Executive Officer of the Company.

Thornhill Medical’s MOVES® SLC™ deployed as part of the first En-Route Care System (ERCS) aboard the U.S. Navy’s Eisenhower Strike Group (IKECSG)

Retrieved on: 
Tuesday, November 28, 2023
Trauma, Suction, ERCS, Oxygen, Commander, IKE, Patient, Nursing care plan, Vital signs

Deployed on October 14, 2023, the ERCS allows the U.S. Navy to evacuate critically ill patients while maintaining full medical capabilities back on the ship.

Key Points: 
  • Deployed on October 14, 2023, the ERCS allows the U.S. Navy to evacuate critically ill patients while maintaining full medical capabilities back on the ship.
  • As a component within the ERCS, MOVES® SLC™ enables expanded care capabilities advanced technology that is smaller, lighter, more durable, flexible, easy to maintain, and less reliant on supply chain.
  • MOVES® SLC™ is a portable life support system that provides advanced critical care capabilities in extreme or austere environments and in transport or evacuation.
  • “We are excited to expand the strike group’s medical response capabilities with the addition of ERCS,” said Cmdr.

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Retrieved on: 
Monday, November 27, 2023
BAL, Food, IND, Movement, Natural killer T cell, Bronchoalveolar lavage, IPF, Blood, Doctor of Philosophy, Serum, Pharmacokinetics, Oxygen, Biomarker, Interim, GRI, Safety, NKT, Vital signs, Sales

LA JOLLA, CA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (“IND”) application for GRI-0621 for the treatment of IPF. The Company plans to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, on track to commence before year end.

Key Points: 
  • The Company plans to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, on track to commence before year end.
  • “Clearance of our IND application for GRI-0621 represents a significant milestone for the Company and for our innovative pipeline of NKT cell modulators.
  • Our team has worked tirelessly to meet our planned milestones and I am proud of the continued progress made.
  • Click here to watch a brief video from the GRI Bio management team discussing the IND clearance and the meaning of this milestone for the Company’s GRI-0621 development program.

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

Retrieved on: 
Monday, December 18, 2023
Health, FDA, Parenting, Medical Devices, Baby, Maternity, Hospitals, Health Technology, Consumer, PR, Multimedia, Stork, Loma Linda University, Research, NICU, Parent, Hospital, Incidence, Pulse, Pediatrics, Hospital medicine, Motion, Skin temperature, Temperature, MASI, Retinopathy, QHD, Oxygen saturation (medicine), Extremis, Perfusion, ARMS, Patient, Safety, Vital signs, Skin, Child, Pharmaceutical industry

Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.

Key Points: 
  • Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby monitoring system, for prescription use with healthy and sick babies 0-18 months of age.
  • Leveraging the same Masimo sensor technology that monitors more than 10 million babies in hospitals every year, Stork provides continuous, accurate monitoring of a baby’s health.
  • In addition, Stork alerts parents if their baby turns over and is sleeping face down, which can be dangerous for babies.
  • For prescription use, Masimo Stork is 510(k) cleared for the following intended use: Masimo Stork is a wearable device intended for the monitoring of multiple physiological parameters.

Livestock Monitoring Market worth $19.37 billion by 2030, at a CAGR of 17.9%, says Coherent Market Insights

Retrieved on: 
Friday, December 22, 2023
MSD, Cattle, Livestock, Government, Software, GPS, Milk, Compound annual growth rate, Farmer, Schering-Plough, Health, Disease, Animal, Behavior, Artificial intelligence, Breeding, Machine learning, DeLaval, Food security, Growth, RFID, Safety, Organization, Vital signs, Algorithm, Agriculture

As per the recent analysis by Coherent Market Insights, the global livestock monitoring market size was valued at US$ 5.2 billion in 2022 and is predicted to reach US$ 19.37 million by 2030.

Key Points: 
  • As per the recent analysis by Coherent Market Insights, the global livestock monitoring market size was valued at US$ 5.2 billion in 2022 and is predicted to reach US$ 19.37 million by 2030.
  • This in turn helps in maximizing livestock productivity and reducing losses, thereby driving the demand for livestock monitoring solutions.
  • Livestock monitoring systems help in complying with these regulations by providing real-time monitoring and data analytics on animal health and well-being.
  • In conclusion, the livestock monitoring market presents lucrative opportunities for growth, driven by the increasing demand for efficient and sustainable livestock management practices.

Livestock Monitoring Market worth $19.37 billion by 2030, at a CAGR of 17.9%, says Coherent Market Insights

Retrieved on: 
Friday, December 22, 2023
MSD, Cattle, Livestock, Government, Software, GPS, Milk, Compound annual growth rate, Farmer, Schering-Plough, Health, Disease, Animal, Behavior, Artificial intelligence, Breeding, Machine learning, DeLaval, Food security, Growth, RFID, Safety, Organization, Vital signs, Algorithm, Agriculture

As per the recent analysis by Coherent Market Insights, the global livestock monitoring market size was valued at US$ 5.2 billion in 2022 and is predicted to reach US$ 19.37 million by 2030.

Key Points: 
  • As per the recent analysis by Coherent Market Insights, the global livestock monitoring market size was valued at US$ 5.2 billion in 2022 and is predicted to reach US$ 19.37 million by 2030.
  • This in turn helps in maximizing livestock productivity and reducing losses, thereby driving the demand for livestock monitoring solutions.
  • Livestock monitoring systems help in complying with these regulations by providing real-time monitoring and data analytics on animal health and well-being.
  • In conclusion, the livestock monitoring market presents lucrative opportunities for growth, driven by the increasing demand for efficient and sustainable livestock management practices.